Inflammatory Bowel Disease in Hispanics: The University of Puerto Rico IBD Registry by Torres, Esther A. et al.
Hindawi Publishing Corporation
International Journal of Inﬂammation
Volume 2012, Article ID 574079, 5 pages
doi:10.1155/2012/574079
Research Article
Inﬂammatory BowelDiseaseinHispanics: TheUniversity of
Puerto Rico IBD Registry
Esther A. Torres,1 AbdielCruz,1 Mariola Monagas,2 Marina Bernal,3 Yadira Correa,1
Rafael Cordero,1 andV´ ıctorL.Carlo1
1UPR Center for Inﬂammatory Bowel Disease, Department of Medicine, UPR School of Medicine, San Juan, PR 00936-5067, USA
2Department of Ophthalmology, UPR School of Medicine, San Juan, PR 00936-5067, USA
3UPR School of Medicine, San Juan, PR 00936-5067, USA
Correspondence should be addressed to Esther A. Torres, etorres@pol.net
Received 12 September 2011; Revised 29 October 2011; Accepted 7 November 2011
Academic Editor: David Sachar
Copyright © 2012 Esther A. Torres et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
A registry of patients with inﬂammatory bowel diseases, ulcerative colitis (UC) and Crohn’s disease (CD), was created at the
University of Puerto Rico in 1995. Subjects with a documented diagnosis of IBD by clinical, radiologic, endoscopic, and/or
pathologic criteria were recruited from the IBD clinics, support groups, and community practices, and demographic and medical
data was collected. All entries from 1995 to 2009 were analyzed for demographics, family history, disease extent, extraintestinal
manifestations,surgery,andsmokinghistory.Resultsweredescribedusingsummarystatistics.635HispanicslivinginPuertoRico,
299 with UC and 336 with CD, were included. Mean ages were 40.3 for UC and 30.9 for CD. Over half (56%) of UC and 41% of
CD were females. Family history was present in 19.3% of UC and 17.5% of CD. Surgery for IBD had been performed in 31.9%
of UC and 51.2% of the CD patients. Over one-fourth of the patients reported extraintestinal manifestations, most frequently
arthropathies. Our ﬁndings contribute to the limited epidemiologic and clinical data on Hispanics with IBD.
1.Introduction
The study of Crohn’s (CD) and ulcerative colitis (UC) has
been focused on Caucasians, as the incidence and diagnosis
ofinﬂammatoryboweldisease(IBD)havebeenmoreevident
in this population. The rates of UC and CD are highest in
northern climates, in urban regions, and in well-developed
areas of the world such as North America and Europe and
lowest in southern climates and underdeveloped areas [1–4].
The reported prevalence of IBD in adults in the United States
(US) has ranged from 37 to 238 per 100,000 for UC and 26
to 201 per 100,000 for CD [4, 5].
The epidemiology of IBD seems to be changing. Inci-
dence in North America, Northern and Western Europe has
stabilized, and low incidence areas are showing an increase
[4]. The racial and ethnic diﬀerences also seem to be nar-
rowing. Reports of IBD from Barbados and the French West
Indies in the Caribbean illustrate these changes [6, 7].
There is an increasing recognition of IBD in the minority
populations of the United States [7–16], and several studies
havedescribedtheepidemiologyofIBDinthesepopulations.
Many of these studies have centered on blacks with IBD,
while IBD in Hispanics is less well deﬁned. The incidence
and prevalence of IBD in Puerto Rico has been rising over
the past decades [17–19]. With the aim of further examin-
ing Hispanics with IBD, we describe the demographic and
clinical characteristics of a large university-based registry of
IBD in Hispanics living in Puerto Rico.
2.MaterialsandMethods
The University of Puerto Rico IBD Registry was created in
1995 [17]. The Registry is a database of patients with UC
and CD that collects demographic and medical information
at the time of interview. Subjects with documented diagnosis
of IBD by clinical, radiologic, endoscopic, and/or pathologic
criteria are recruited from the IBD clinics, support group,
and community practices and represent diverse areas of
Puerto Rico. After informed consent, data is collected2 International Journal of Inﬂammation
through an interview by trained investigators and medical
records review. Information collected includes age, gender,
diagnosis, age at onset of symptoms, age at diagnosis, urban
or rural living, place of birth and parentage, family history of
IBD, smoking history, extraintestinal manifestations, extent
of disease, medications, and surgery. Method of diagnosis,
including endoscopic procedures, imaging, pathologic spec-
imens, and surgical ﬁndings, is obtained from the treating
physician’s and/or clinic medical record. The diagnosis has
to be established or conﬁrmed by a gastroenterologist. No
followup is provided for updating data in the study. The
database is entered into an Excel spreadsheet. The Registry
has continuing Institutional Review Board approval from
the University of Puerto Rico Medical Sciences Campus
(protocol no. 1250195).
This report includes only Hispanics living in Puerto
Rico. Hispanic subjects were identiﬁed by having both
parents of Puerto Rican, Dominican, Venezuelan, or Cuban
origin. Place of birth and childhood home are recorded in
the Registry. Five subjects were excluded because of non-
Hispanic origins (two from the United States, one from
Nevis, one from Israel, and one with a German mother). The
vast majority of subjects (585) were born in Puerto Rico of
Puerto Rican parents. Forty-four were born in the United
States, three in the Dominican Republic, three in Cuba, and
one in Venezuela.
All entries from 1995 until 2009 were analyzed for dem-
ographics, family history, smoking history, disease extent,
extraintestinal manifestations, and surgery. Disease duration
at the time of inclusion in the Registry was calculated from
the time of symptom onset and from the time of diagnosis.
Medications used have been reported in a separate study
[20]. Summary measures were used to describe the study
group.
3. Results
Six hundred thirty-ﬁve Hispanic patients, 299 (47.1%) with
UC and 336 (52.9%) with CD, were included in the Registry
during the study period. The ages ranged from 10 to 85
years old, with the youngest recording age of diagnosis at 7
years old. Table 1 shows the demographics, family history,
andsmokinghistoryofthepopulationincludedinthisstudy.
Patients with UC were older, predominantly female, and
smoked less at the time of diagnosis, when compared to
patients with CD. Mean age for UC patients was 40.3 ± 15.6
with mean ages at onset of 31 ± 14.4 and at diagnosis of
32.6 ± 14.4. Mean age for CD patients was 30.9 ± 12.2,
with a mean age at onset of 24.7 ± 11.7 and at diagnosis of
26.8±12.6. For ulcerative colitis, interval from onset was 9.3
years and interval from diagnosis was 7.7 years. For Crohn’s
disease, interval from onset was 6.2 years and interval from
diagnosis was 4.1 years. More than half (56%) of UC patients
werefemales,whereas59%ofCDpatientsweremales.Nearly
12% of IBD patients were smokers at the time of diagnosis.
Family history of IBD was present in 19.3% of UC and
17.5% of CD patients. In the cohort with UC, there were 28
ﬁrstdegreerelativeswithUCand4withCD.Anadditional27
other relatives had UC and 4 had CD. For patients with CD,
Table 1: General characteristics of the Registry patients.
UC CD
n 299 336
Male:female(%) 44:56 59:41
Mean age 40.3 ±15.63 0 .9 ±12.2
Mean age onset 31 ±14.42 4 .7 ±11.7
Mean age dx 32.6 ±14.42 6 .8 ±12.6
Family history IBD n (%) 58 (19.3%) 59 (17.5%)
Smoking at dx (%) 10% 13.7%
CD: Crohn’s disease; UC: ulcerative colitis; IBD: inﬂammatory bowel
disease.
Table 2: Extraintestinal manifestations.
UC (%) CD (%) Total IBD
(%)
EIM 78 (26) 93 (27.6) 171 (26.9)
All arthropathies 58 (19.4) 76 (22.8) 134 (21.1)
Peripheral arthropathy 48 (16.1) 62 (18.4) 110 (17.3)
Ankylosing spondylitis 2 (0.7) 1 (0.3) 3 (0.5)
Sacroiliitis 8 (2.6) 13 (3.8) 21 (3.3)
Erythema nodosum∗ 5 (1.6) 23 (6.8) 28 (4.4)
Pyoderma gangrenosum 6 (2) 3 (0.9) 9 (1.4)
Uveitis and/or episcleritis 5 (1.7) 10 (3) 15 (2.4)
Primary sclerosing
cholangitis 3 (1.0) 2 (0.6) 5 (0.8)
Osteoporosis 6 (2.0) 14 (4.1) 20 (3.1)
∗P<0.002.
17 ﬁrst-degree relatives (parents, siblings, or oﬀspring) were
aﬀected with CD and 28 with UC. Twenty-six more remote
relatives (including grandparents, aunts/uncles, cousins and
nephews/nieces) had CD and 27 had UC.
At the time of inclusion in the UPR IBD Registry, the
disease extent in subjects with UC was as follows: 13%
proctitis, 16.2% proctosigmoiditis, 21% left side colitis, and
49.6% pancolitis. In subjects with CD, 54.4% had ileal
disease, 47% had colon involvement, 15.6% had perianal
disease, 6.7% had jejunal disease, and 1.1% had upper
gastrointestinaltractinvolvement.31.9%ofUCandoverhalf
(51.2%) of CD patients reported having surgery for IBD at
the time of the interview.
Extraintestinal manifestations, reported in 171 patients,
are shown in Table 2. The most common were the various
arthropathies, similar in both UC and CD, followed by
erythema nodosum, which was more frequent in CD (1.6%
in UC versus 6.8% in CD, P<0.002). Osteoporosis
was found more frequently in CD, though not statistically
signiﬁcant (14 of 20 cases). Ophthalmologic manifestations
were grouped together, as they were infrequent.
4. Discussion
Incidenceand prevalencestudies forPuerto Ricohaveshown
anincreaseinbothulcerativecolitisandCrohn’sdiseasesince
the late 1990s [17–19].International Journal of Inﬂammation 3
Table 3: Crohn’s disease: comparison with other Hispanic populations.
UPR Registry
PR (NIDDK-
IBDGR)
[7]
Spain [21]P o r t u g a l [ 22] Huelva, Spain
[23]
n 336 106 635 1692 30
Male:female (%) 59:41 48:52 44:56 57:43
Mean age 30.9 33 31
EIM (%) 27.6 36.7
Fam hx IBD (%) 17.5 16.6 15 5.8 33.3
Table 4: UC: comparison with other Hispanic populations.
UPR Registry PR (NIDDK
IBDGRC) [7] Mexico [24] Panama [25] Argentina [25]F Huelva, Spain
[23]
n 299 62 848 15 38 40
Male:female (%) 44:56 45:55 60:40 39:61 45:55
Mean age 40.3 31.3 38 45
EIM (%) 26 41.5 12.5
Fam hx IBD (%) 19.3 14.5 6.7 12.5
The clinical presentation of IBD in Hispanics has not
been well studied. Most of the published studies focus
on incidence and prevalence with limited descriptions of
clinical characteristics. Studies in which Hispanics with IBD
are compared with Caucasians and other ethnic or racial
populations are limited by the small number of Hispanics
included. A study of 148 patients with IBD seen from 1999
to 2003 compared 58 Whites, 54 African Americans, and
30 Mexican Americans. Family history was present in only
10% of Mexican Americans as compared to 33% of Whites.
In those with ulcerative colitis, no diﬀerences in treatment
and surgery were found [13]. In another study comparing
the same three groups (H, AA, W), there was no diﬀerence
between African Americans and Mexican Americans when
separately compared to Whites in terms of intestinal mani-
festations of CD and UC, respectively. Among UC patients,
Whites had signiﬁcantly higher incidence than Mexican
Americans of joint symptoms (P<0.0001) and osteoporosis
(P = 0.001). Whites had a stronger family history of IBD
and colorectal carcinoma. All the Mexican Americans with
UC who were tested had positive p-ANCA compared to only
40% of Whites (P = 0.033). Proctitis alone occurred in 32%
of Whites, but only in 9% of Mexican Americans with UC
(P = 0.022). In general, there were no signiﬁcant diﬀerences
inmedicaltreatment,surgeries,orhospitalizationsintheUC
andintheCDgroups.Insummary,MexicanAmericanswith
IBD diﬀered signiﬁcantly from other ethnic groups in the
distribution of IBD subtypes, family history, and serological
markers [10].
A recent large study from the United States involv-
ing 1,126 subjects with IBD, of which 830 were White,
169 were Puerto Rican Hispanics, and 127 were African
Americans, reported that Hispanics were at higher risk of
developing perianal disease and erythema nodosum. Among
UC patients, Hispanics had more proximal disease extent.
Hispanics with CD, but not UC, had lower prevalence of
family history of IBD than Whites. Hispanics were more
likely to have undergone bowel diversion for CD (22.4%
versus 7.4%, P = 0.001) but had fewer total surgeries
for abdominal CD than Whites. The number of surgeries
for perianal CD was similar among all racial groups. At 5
years, the proportion of surgery-free CD patients was 68%
for Whites and 60% for Hispanics. The median survival
time free from surgery was 9.8yr for Whites and 6.6yr
for Hispanics, with no signiﬁcant increased risk of CD-
related surgery for Hispanics compared to white subjects.
Hispanics had a higher prevalence of surgery indicated for
chronic refractory UC (85.7% versus 40.7%, P<0.001).
Furthermore, Hispanics had a considerably higher rate of
colectomy for any indication (chronic disease, dysplasia, or
fulminant colitis) than white subjects (32.3% versus 15.8%,
P<0.01) [7].
A comparison between our UPR IBD Registry and other
Hispanic populations including Puerto Rico [7], Spain [21],
Portugal [22],Huelva,Spain[23],Mexico[24],Panam´ a[25],
and Argentina [25] is shown in Tables 3 (CD) and 4 (UC).
It includes gender distribution, mean age, family history
of IBD, and percent with extraintestinal manifestations.
The comparison is limited by a number of small studies,
the data reported for each population, and the period
included in the study. As IBD incidence is considered to be
increasing in Hispanics, earlier studies such as the one from
Argentina and Panam´ a may not be representative of actual
population characteristics. A systematic review of IBD in
Asians, Hispanics, and African Americans published in 2009
concludes that, although the incidence is rising in Hispanics,
the literature regarding IBD manifestations is very limited
[26].4 International Journal of Inﬂammation
5. Conclusions
Variation in ﬁndings between diﬀerent Hispanic groups may
be a result of a changing epidemiology accompanying a
rising incidence of IBD, with earlier studies being unable to
detect an increase in family history or the true prevalence
of extraintestinal manifestations, as well as an evolution in
diseasephenotype overtime. Diﬀerences between whites and
Hispanics reported in various studies are not consistent.
These may be related to study design, small numbers of
Hispanics in the studies, true genetic variation, and envi-
ronmental inﬂuences. The limited inclusion of minorities in
researchstudies, partlydueto thelow incidence ofIBDatthe
time, but also possibly secondary to underrecruitment, poor
interest in participation and referral bias, may also aﬀect the
results.
More studies are needed for a better characterization and
comparisonofepidemiologyandclinicalpresentationofIBD
in Hispanics. This knowledge may impact the therapeutic
approach to these patients as well as the development of
health care strategies to improve access and outcomes.
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